People with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis are at particularly high risk for progression to cirrhosis or hepatocellular carcinoma if they have diabetes, say researchers.
People with type 1 diabetes are approximately twice as likely to experience gastrointestinal symptoms as those without, and these symptoms are associated with poor glycemic control and quality of life, study results suggest.
Researchers from the DiRECT trial have reported large positive effects on liver fat and insulin secretion among people who achieved type 2 diabetes remission in response to a very-low-calorie diet.
Research shows that changes in markers of the metabolic syndrome and fatty liver disease are present more than 20 years before people receive a diagnosis of type 2 diabetes.
Researchers presented the results of several studies investigating the risks associated with nonalcoholic fatty liver disease and potential treatment strategies at the EASD annual meeting in Lisbon, Portugal.
Results of a randomized trial suggest that patients with type 2 diabetes experience metabolic benefits from a hypocaloric diet regardless of whether it is low in fat or low in carbohydrate content.
Results of a randomized trial suggest that the sodium-glucose cotransporter 2 inhibitor ipragliflozin has equivalent efficacy to pioglitazone for the treatment of patients with type 2 diabetes complicated by nonalcoholic fatty liver disease.
This article reviews the pathophysiology, clinical presentation, epidemiology, and management of diabetic enteropathy, aiming to provide a practical approach to this often under-recognized and challenging complication of diabetes.